spondylitis

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis.

Ciproquazone has analgesic activity and is used to treat spondylitis.

Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Aceclofenac (Preservex) is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties.

SGC-CBP30 is an effective CREBBP EP300 inhibitor (IC50: 21 38 nM).

Salazosulfamide has shown potential in the treatment of ankylosing spondylitis, according to research studies.

Azapropazone is anti-inflammatory agent. Azapropazone has uricosuric properties used to treat rheumatoid arthritis and ankylosing spondylitis. Azapropazone lowered plasma uric acid but exerted only a modest and variable uricosuric effect without altering

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is utilized in research on immune disorders [including rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus] and cancer.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Gumokimab (AK 111), a monoclonal antibody, targets IL-17A and is utilized in researching psoriasis and ankylosing spondylitis. It competitively inhibits the interaction between human IL-17A and its receptor, IL-17R.

Certolizumab is an antibody that helps relieve pain and swelling in arthritis. It works by blocking tumor necrosis factor (TNF). It is being studied for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease.